<DOC>
	<DOCNO>NCT02236078</DOCNO>
	<brief_summary>Multidrug-resistant ( MDR ) tuberculosis ( TB ) must treat second-line drug ( SLD ) less effective , toxic , expensive . Treatment require least 20 month 4 effective drug base timely drug susceptibility test ( DST ) result . However , many example closely related drug differ antimicrobial activity . Labs find difference DST result among rifamycins , rifampin ( RMP ) rifabutin ( RBT ) ; fluoroquinolones , ofloxacin moxifloxacin ; second-line injectable agent , kanamycin , amikacin , capreomycin . In related finding , isolate resistant 0.2 mcg/ml INH may susceptible high concentration . In Preserving Effective Tuberculosis Treatment Study ( PETTS ) , 32 % RMP-resistant isolates susceptible RBT , 41 % kanamycin-resistant isolates susceptible capreomycin , 45 % isolates resistant 0.2 mcg/ml INH susceptible 1.0 5.0 mcg/ml ( 1 ) . Other study demonstrate difference DST result moxifloxacin ofloxacin . Whether vitro result translate clinical efficacy completely unknown . Given severely limited treatment option MDR TB , would exceedingly useful know whether vitro result translate evidence clinically meaningful treatment decision . The investigator determine clinical bactericidal activity certain antibiotic M. tb appear effective vitro even though closely relate drug class ineffective vitro . Further , investigator propose determine molecular genetic determinant difference . Specifically , plan determine : 1 . The bactericidal activity RBT patient whose baseline DST result demonstrate susceptibility RBT resistance RMP . 2 . The bactericidal activity high-dose INH patient whose baseline DST result demonstrate susceptibility high concentration INH resistance low concentration INH . 3 . The bactericidal activity RMP approve molecular assay demonstrate genetic mutation associate RMP resistance , phenotypic test demonstrates susceptibility RMP . 4 . The bactericidal activity moxifloxacin patient whose baseline DST result demonstrate susceptibility moxifloxacin resistance ofloxacin . 5 . The bactericidal activity amikacin capreomycin patient whose baseline DST result demonstrate susceptibility either two drug resistance kanamycin . 6 . The genetic mutation associate vivo vitro drug resistance bactericidal activity . To achieve objective investigator propose innovative variation early bactericidal activity ( EBA ) study methodology . Patients risk MDR TB screen RMP resistance INH resistance use molecular assay . In RMP-resistant INH-resistant TB , investigator quickly perform phenotypic DSTs use direct method Bactec Mycobacterium Growth Indicator Tube ( MGIT ) 960 system , result available within 14-21 day . If DST result show , example , RMP resistance susceptibility RBT , consent patient treat RBT 10 day . The investigator assess effect serial quantitative sputum culture . If concentration viable bacteria decrease significantly , investigator interpret mean drug effect . If , drug ineffective . After 10 day , patient resume individualized multidrug treatment base full set DST result . In case investigator identify drug effective condition , investigator sequence know putative gene associate action drug mycobacterial isolates patient . The result would immediate implication treatment MDR TB diagnostic mycobacteriology .</brief_summary>
	<brief_title>Brief Bactericidal Activity Anti-Tuberculosis Drugs</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Capreomycin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Written inform consent RMP and/or INH resistance approve molecular genetic test Phenotypic drug susceptibility test result match one require pattern Sputum microscopy positive acid fast bacilli Ineligible MDR TB treatment accord national guideline HIV infection CD4 count le 50 Pregnancy Incarceration Too sick participate ( Karnofsky score &lt; 60 , arterial pO2 &lt; 90 , respiratory rate repeatedly &gt; 25/min , clinician 's judgment ) Hepatic enzymes &gt; 3x normal Estimated glomerular filtration rate &lt; 60 mL/min/1.73 m2 Unable provide adequate sputum specimen</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>